Atman Shah
Interventional Cardiology · Chicago, ILNPI 1033138557
Payments from drug & device makers
Across 993 payments — averaging $799.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$651K
- AstraZeneca$132K
- Maquet Cardiovascular L.L.C.$2K
- Getinge USA Sales, LLC$2K
- Edwards Lifesciences$1K
- Inari Medical, Inc.$1K
- plus $4K from 22 others
What the payments were for
- Consulting fees$481,60861%
- Speaking & faculty fees$187,45624%
- Travel & lodging$102,44013%
- Food & beverage$16,8352%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 736 | $651,366 |
| AstraZeneca | 122 | $132,134 |
| Maquet Cardiovascular L.L.C. | 1 | $2,100 |
| Getinge USA Sales, LLC | 1 | $1,600 |
| Edwards Lifesciences | 14 | $1,478 |
| Inari Medical, Inc. | 34 | $1,362 |
| Datascope Corp. | 1 | $1,200 |
| Ancora Heart, Inc. | 2 | $755 |
| Medtronic | 8 | $346 |
| Pfizer | 17 | $303 |
| Boston Scientific | 6 | $238 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $216 |
| Stryker | 7 | $176 |
| Amgen | 5 | $130 |
| Novartis | 5 | $99 |
| Acist Medical Systems, Inc. | 4 | $90 |
| Cardiva Medical, Inc. | 5 | $74 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Teleflex LLC | 2 | $44 |
| Astellas Pharma US Inc | 2 | $37 |
| Cardiovascular Systems Inc. | 1 | $36 |
| Elutia, Inc. | 2 | $31 |
| Abiomed | 1 | $28 |
| Merck | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Shockwave Medical, Inc | 1 | $16 |
| ZOLL Circulation Inc | 1 | $15 |
| Philips North America LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER AMULET$505,501
- BRILINTA$129,941
- AMPLATZER Occluders$86,182
- NAVITOR$24,690
- AMPLATZER$4,796
- AMPLATZER PICCOLO$4,400
- AMPLATZER TALISMAN$3,985
- MitraClip$2,200
- Vasoview Hemopro 2$2,100
- Xience V coronary stent system$1,650
- CARDIOHELP$1,600
- CARDIOSAVE HYBRID, TYPE B PLUG$1,200
- AccuCinch$755
- Cardiovascular- Research only$709
- EVOQUE$631
- FLOWTRIEVER CATHETER, S$433
- CT THROMBECTOMY SYSTEM KIT$433
- PORTICO$395
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$343
- COREVALVE EVOLUT R$197
How this compares
$793,966 in reported general payments places this provider in the 95th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 28 | $42,107 |
| EliquisApixaban | 20 | $20,088 |
| FarxigaDapagliflozin Propanediol | 12 | $16,090 |
| Metoprolol Succinate | 60 | $817 |
| Ezetimibe | 13 | $559 |
| Carvedilol | 37 | $504 |
| Rosuvastatin Calcium | 22 | $399 |
| Atorvastatin Calcium | 45 | $365 |
| Potassium Chloride | 14 | $336 |
| ClopidogrelClopidogrel Bisulfate | 37 | $328 |
| Amlodipine Besylate | 37 | $276 |
| Losartan Potassium | 12 | $182 |
| Spironolactone | 19 | $173 |
| Furosemide | 24 | $122 |
| Pravastatin Sodium | 11 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $99 | $42,10728 claims |
| PfizerEliquis | $303 | $20,08820 claims |
| AstraZenecaFarxiga | $132,134 | $16,09012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Chicago
- Charles DavidsonChicago$5.8M
- Laura DavidsonChicago$661K
- Hussam SuradiChicago$455K
- Fareed Moses ColladoChicago$278K
- Keith BenzulyChicago$271K
- David StewartChicago$241K
- Sandeep KhoslaChicago$228K
- Daniel SchimmelChicago$221K
- Ranya SweisChicago$120K
- Anita AsgarChicago$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.